RenovoRx Inc. Common Stock (RNXT)

About RNXT

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headqua…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

17

Website

renovorx.com/

Fundamentals

1-day range

$1.15$1.34

Market cap

$51.86M

P/E (trailing)

—

P/E (forward)

-8.48

EPS (trailing)

$-0.33

Dividend yield

—

Beta

0.86

Avg. volume

329.7K

Forecasts

4 analyst ratings

RenovoRx Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RNXT

  RenovoRx Inc. Common Stock

  $1.68

  ▲ 13.18%
  Market cap $51.86MP/E —
  $0.7006$1.68
• SCYX

  SCYNEXIS Inc. Common Stock

  $5.44

  ▼ 1.45%
  Market cap $51.64MP/E —
  $3.53$10.48
• IBO

  Impact BioMedical Inc. Common Stock

  $0.444

  ▲ 0.68%
  Market cap $48.61MP/E 0.49
  $0.37$0.83
• TCRT

  Alaunos Therapeutics Inc. Common Stock

  $1.56

  ▼ 6.02%
  Market cap $48.60MP/E —
  $1.55$4.59
• IMMP

  Immutep Limited American Depositary Shares

  $0.3848

  ▲ 1.26%
  Market cap $55.21MP/E —
  $0.028$0.47
• MREO

  Mereo BioPharma Group plc American Depositary Shares

  $0.2545

  ▼ 6.43%
  Market cap $47.46MP/E —
  $0.2$2.37
• CNTX

  Context Therapeutics Inc. Common Stock

  $0.3836

  ▼ 7.79%
  Market cap $46.31MP/E —
  $0.3807$3.62

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
  benzinga · 8/28/2026
• 12 Health Care Stocks Moving In Wednesday's After-Market Session
  Benzinga · 8/12/2026
• RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M Est
  Benzinga · 8/12/2026
• RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K Estimate
  Benzinga · 8/12/2026
• EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027
  Benzinga · 8/11/2026
• 12 Health Care Stocks Moving In Monday's After-Market Session
  Benzinga · 8/10/2026

• Mark Voll · May 19, 2026 · Buy

  25.0K @ $0.7876
• Shaun Bagai · April 3, 2026 · Grant

  946.1K
• Gentry Leesa · April 3, 2026 · Grant

  128.6K
• Ramtin Agah · April 3, 2026 · Grant

  621.7K
• Mark Voll · April 3, 2026 · Grant

  80.0K
• Mark Voll · March 25, 2026 · Grant

  12.4K
• Laurence Marton · March 20, 2026 · Buy

  4.9K
• Laurence Marton · March 20, 2026 · Buy

  9.7K
• Shaun Bagai · March 20, 2026 · Buy

  12.2K
• Shaun Bagai · March 20, 2026 · Buy

  24.3K
• Mark Voll · March 20, 2026 · Buy

  48.6K
• Mark Voll · March 20, 2026 · Buy

  97.2K

Institutional Ownership

March 31, 2026

Total shares held

8.41M

Total value held

$8.38M

Institutional holders

30